longer subject to Section 16. Form 4 or

Form 5 obligations

may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(11mt of 1y	pe Response	~)														
Name and Address of Reporting Person * Pauls Dietrich John			2. Issuer Name and Ticker or Trading Symbol DiaMedica Therapeutics Inc. [DMAC]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner					
TWO CARLSON PARKWAY, SUITE 260				3. Date of Earliest Transaction (Month/Day/Year) 07/28/2021								X Officer (give title below) Other (specify below) President and CEO				
(Street) MINNEAPOLIS, MN 55447			4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person					
(Cit		(State)	(Zip)			Т	able I - 1	Non-Deri	vative S	ecuritie	es Acquire	d, Disposed o	of, or Benef	icially Owne	d	
1.Title of S (Instr. 3)	2. Transaction Date (Month/Day/Ye) Voting Common Shares, no par value per share				Date, if Code (Instr		(4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		of (D) Ov Tr	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		I	Ownership Form:	Beneficial	
				(Month/Day/Year)		/Year)	Code V		Amount (A) or (D) F		,	nstr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
_											30	30,804 (1)			D	
	Report on a s	separate line for each	n class of securities b	peneficia	lly own	ned direc	etly or in	Person				ollection of				1474 (9-02)
	Report on a s	separate line for each		- Deriva	itive Se	ecurities	s Acquir	Persons in this f a curren	orm are ntly vali	not reid OME	equired to 3 control ficially Ov	respond u number.				1474 (9-02)
	2. Conversion or Exercise Price of Derivative Security	3. Transaction	Table II 3A. Deemed Execution Date, if	- Deriva (e.g., p 4. Transac Code	stive Se uts, cal 5. Se Se or (D (Ir	Numbe erivative ecurities cquired	s Acquir rants, op r of 6. Ex (A) ed of	Persons in this f a curre	orm are ntly valid sed of, on the reisable and the reisable are	e not re id OME or Bene e securi	equired to 3 control ficially Ov ities)	o respond unumber. vned d Amount ying	8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported Transactions	f 10. Owners: Form of Derivati Security Direct (i or Indirects)	11. Nature of Indire Benefici Owners! (Instr. 4)
Reminder: 1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II 3A. Deemed Execution Date, if any	- Deriva (e.g., p 4. Transac Code	stive Se uts, cal 5. Se Se or (D (Ir	Numbe erivative ecurities cquired Dispose D)	s Acquirrants, oper of 6. Ex. (A) ed of 4,	Persons in this f a current red, Disportions, control Date Exe Expiration 1	orm are ntly vali sed of, o nvertible reisable a Date //Year)	e not reid OME or Bene e securi	equired to 3 control ficially Ovities) 7. Title an of Underly Securities	o respond unumber. vned d Amount ying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Ownersi Form of Derivati Security Direct (l or Indire	11. Nature of Indire Benefici Owners! (Instr. 4)

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Pauls Dietrich John TWO CARLSON PARKWAY SUITE 260 MINNEAPOLIS, MN 55447	X		President and CEO				

Signatures

07/29/2021
Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.

 $\begin{tabular}{ll} \textbf{(2)} Vests in sixteen nearly equal quarterly installments over four years. \\ \end{tabular}$

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.